top of page

Agios on today’s phase 2 data for the pyruvate kinase activator mitapivat in sickle cell disease

Brian Goff, CEO of Agios Pharma, on today's phase 2 SCD data and how he thinks maitapivat can fit into the competitive landscape.



Comments


Join the BiotechTV mailing list

Thanks for subscribing!

bottom of page